AL3818 or placebo clinical trials

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

This study is looking at a new medicine called AL3818 (anlotinib) for people with advanced alveolar soft part sarcoma (ASPS). It aims to see how safe and effective it is. Currently, it's only for ASPS patients.